PBPIA
OCS icon

Pivotal bioVenture Partners Investment Advisor’s Oculis Holding OCS Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio OCS Stock Details OCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9M Sell
1,506,250
-174,033
-10% -$3.95M 6.79% 7
2026
Q1 		$44.7M Sell
1,680,283
-608,375
-27% -$16.1M 15.97% 2
2025
Q4 		$45.7M Sell
2,288,658
-12,116
-0.5% -$242K 17.67% 2
2025
Q3 		$40.4M Hold
2,300,774
– – 23.38% 2
2025
Q2 		$44.7M Hold
2,300,774
– – 27.68% 1
2025
Q1 		$43.8M Buy
2,300,774
+563,078
+32% +$11.5M 35.43% 1
2024
Q4 		$29.5M Buy
1,737,696
+141,778
+9% +$2.23M 19.95% 2
2024
Q3 		$19.6M Hold
1,595,918
– – 11.61% 4
2024
Q2 		$19.1M Hold
1,595,918
– – 14.66% 3
2024
Q1 		$19.2M Sell
1,595,918
-292,870
-16% -$3.51M 12.36% 4
2023
Q4 		$21.2M Sell
1,888,788
-329,966
-15% -$3.42M 5.38% 3
2023
Q3 		$24.4M Sell
2,218,754
-162,442
-7% -$2.04M 9.73% 3
2023
Q2 		$29.4M Hold
2,381,196
– – 9.68% 3
2023
Q1 		$17.7M Buy
+2,381,196
New +$19.9M 7.29% 4

Other funds holding OCS

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's OCS Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor reduced its Oculis Holding (OCS) stake by 10% in Q2 2026, selling an estimated $3.95M and leaving 1,506,250 shares worth $20.9M. The position accounts for 6.79% of the portfolio, ranked #7.

Pivotal bioVenture Partners Investment Advisor first reported a position in OCS in Q1 2023 and has held it in 14 quarters since. The position peaked at $45.7M in Q4 2025. 59 funds tracked by Wall St. Rank hold OCS as of Q2 2026.

  • Pivotal bioVenture Partners Investment Advisor held 1,506,250 shares of Oculis Holding worth $20.9M as of Q2 2026.
  • Pivotal bioVenture Partners Investment Advisor sold 174,033 Oculis Holding shares in Q2 2026, an estimated $3.95M.
  • Oculis Holding made up 6.79% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q2 2026, its #7 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Oculis Holding in Q1 2023 and has held it in 14 quarters since.
  • Pivotal bioVenture Partners Investment Advisor's Oculis Holding position peaked at $45.7M in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oculis Holding as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.